Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642149 | 1.00 | TAAR1 (0.34) | TAAR1EPHX2GAABTKMAPK1 | |
| SCHEMBL5120488 | 1.00 | TAAR1 (0.34) | TAAR1EPHX2GAABTKMAPK1 | |
| SCHEMBL5667133 | 0.97 | TAAR1 (0.36) | TAAR1EPHX2GAABTKMAPK1 | |
| SCHEMBL9937310 | 0.95 | DPP4 (0.33) | TAAR1EPHX2BTKALDH1A1LMNA | |
| SCHEMBL2679564 | 0.90 | TP53 (0.32) | — | |
| SCHEMBL1998545 | 0.90 | TP53 (0.32) | — | |
| SCHEMBL344785 | 0.90 | TP53 (0.32) | — | |
| SCHEMBL5991039 | 0.89 | HRH3 (0.33) | GAAMAPK1 | |
| SCHEMBL18825094 | 0.87 | HRH3 (0.34) | GAAMAPK1ALDH1A1HCRTR2TSHR | |
| SCHEMBL20595095 | 0.87 | CYP4A11 (0.39) | GAAMAPK1ALDH1A1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025202889-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2025-10-02 | — | — | WO | disclosed |
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-02-15 | — | — | US | disclosed |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| EP-3436445-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11725001-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-08-15 | — | — | US | disclosed |
| US-20220402902-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. | 2022-12-22 | — | — | US | disclosed |
| CN-114929691-A | Bicyclic compounds and uses thereof | 爱思开生物制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| US-11242337-B2 | Compounds useful for treating gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3313839-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9896436-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170320879-A1 | A PROCESS FOR THE PREPARATION OF IBRUTINIB | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| EP-3221320-A1 | A PROCESS FOR THE PREPARATION OF IBRUTINIB | Sun Pharmaceutical Industries Ltd (IN) | 2017-09-27 | — | — | EP | disclosed |
| WO-2017161033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2016210165-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016151438-A1 | A PROCESS FOR THE PREPARATION OF IBRUTINIB | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-09-29 | — | — | WO | disclosed |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. | 2016-07-07 | — | — | US | disclosed |
| WO-2016079693-A1 | A PROCESS FOR THE PREPARATION OF IBRUTINIB | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-05-26 | — | — | WO | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402902-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | TAAR1 4367/4885EPHX2 3328/4885GAA 3496/4885 |
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | TAAR1 4445/4885EPHX2 4869/4885GAA 2540/4885 |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | TAAR1 3978/4885EPHX2 2009/4885GAA 511/4885 |
| US-11242337-B2 | Compounds useful for treating gastrointestinal tract disorders | SLC10A2, FABP2, SLC10A1 | TAAR1 416/4885EPHX2 2030/4885GAA 592/4885 |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | TAAR1 4367/4885EPHX2 3328/4885GAA 3496/4885 |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT8 | TAAR1 4497/4885EPHX2 3518/4885GAA 3351/4885 |
| US-20170320879-A1 | A PROCESS FOR THE PREPARATION OF IBRUTINIB | BTK, SYK, IGLV6-57 | TAAR1 4795/4885EPHX2 2724/4885GAA 2096/4885 |
| US-11725001-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | TAAR1 4367/4885EPHX2 3328/4885GAA 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.